drugset / Trial / NCT01807377

Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects

NCT01807377

Phase 1 Completed 15 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.

Timeline

Start
2013-04
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 2 mg
Subject PF-05175157 Small molecule 200 mg Oral